Gut Microbiota: Formation, Lifelong Development and Relation to Cytochrome P450 System, Diseases, Drug Bioavailability and Drug Interactions


Abstract views: 105 / PDF downloads: 67

Authors

DOI:

https://doi.org/10.5152/eurjther.2020.19098

Keywords:

Microbiota, bioavailability, pharmacokinetics, personalized medicine, CYP P450s

Abstract

The human microbiota is an essential and individual part of the human body composed of microorganisms that live in symbiosis with the human body. It is formed prenatally and changes throughout a person’s life due to endogenous and exogenous factors such as birth, geography, gender, sex hormones, genetics, mode of birth, age, lifestyle, nutrition, use of antibiotics, and disease-related changes. Studies on the microbiota have mostly focused on its relation to diseases, but the gut microbiota is also very sensitive to xenobiotics, which directy or indirectly alter the pharmacokinetics of drugs used by the host. Although the gut microbiota recovers in a few weeks, some changes may be permanent. It is important to consider changes in drug bioavailability in patients who were recently or currently treated with antibiotics for the safe and efficient pharmacotherapy of patients. With advanced knowledge about the microbiota and advances in the field of microbiome genetics, it may be possible that in the future, a person’s microbiota map is used in personalizing drug treatment. In this review, we aim to emphasize the importance of microbiota and drug interactions.

Metrics

Metrics Loading ...

Author Biographies

Büşra Cesur, Department of Medical Pharmacology, Akdeniz University School of Medicine, Antalya

Department of Gene and Cell Therapy, Akdeniz University School of Medicine, Antalya

Devrim Demir Dora, Department of Medical Pharmacology, Akdeniz University School of Medicine, Antalya

Department of Gene and Cell Therapy, Akdeniz University School of Medicine, Antalya

References

Sender R, Fuchs S, Milo R. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol 2016; 14: e1002533.

Altuntas Y, Batman A. Mikrobiyota ve metabolik sendrom. Turk Kardiyol Dern Ars 2017; 45: 286-96.

Kootte RS, Vrieze A, Holleman F, Dallinga-Thie GM, Zoetendal EG, de Vos WM, et al. The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus. Diabetes Obes Metab 2012; 14: 112-20.

Biesalski HK. Nutrition meets the microbiome: micronutrients and the microbiota. Ann N Y Acad Sci 2016; 1372: 53-64.

Lebeer S, Spacova I. Exploring human host-microbiome interactions in health and disease-how to not get lost in translation. Genome Biol 2019; 20: 56.

Hasan N, Yang H. Factors affecting the composition of the gut microbiota, and its modulation. PeerJ 2019; 7: e7502.

Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, Jia W, et al. Host-gut microbiota metabolic interactions. Science 2012; 336: 1262-7.

Moore RE, Townsend SD. Temporal development of the infant gut microbiome. Open Biol 2019; 9: 190128.

Peterson J, Garges S, Giovanni M, Mcinnes P, Wang L, Schloss JA, et al. The NIH human microbiome project. Genome Res 2009; 19: 2317- 23.

Cusack S, Paul WO. Challenges and implications for biomedical research and intervention studies in older populations: Insights from the ELDERMET study. Gerontology 2013; 59: 114-21.

Claesson MJ, Jeffery IB, Conde S, Power SE. Gut microbiota composition correlates with diet and health in the elderly. Nature 2012; 488:178-84.

Lynch DB, Jeffery IB, Cusack S, O’Connor EM, O’Toole PW. Diet-microbiota-health interactions in older subjects: implications for healthy aging. In Aging and Health-A Systems Biology Perspective. Interdiscip Top Gerontol 2015; 40: 141-54.

Thursby E, Juge N. Introduction to the human gut microbiota. Biochem J 2017; 474: 1823-36.

Lonardo A, Nascimbeni F, Maurantonio M, Marrazzo A, Rinaldi L, Adinolfi LE. Nonalcoholic fatty liver disease: Evolving paradigms. World J Gastroenterol 2017; 23: 6571-92.

Wang Y, Wang B, Wu J, Jiang X, Tang H, Nielsen OH. Modulation of gut microbiota in pathological states. Engineering 2017; 3: 83-9.

Walker RW, Clemente JC, Peter I, Loos RJ. The prenatal gut microbiome: are we colonized with bacteria in utero? Pediatr Obes 2017; 12:3-17.

Vemuri R, Gundamaraju R, Shastri MD, Shukla SD, Kalpurath K, Ball M, et al. Gut Microbial Changes, Interactions, and Their Implications on Human Lifecycle: An Ageing Perspective. Biomed Res Int 2018; 26: 4178607.

Derrien M, Alvarez AS, de Vos WM. The gut microbiota in the first decade of life. Trends Microbiol 2019; 27: 997-1010.

Chong CYL, Bloomfield FH, O’Sullivan JM. Factors Affecting Gastrointestinal Microbiome Development in Neonates. Nutrients 2018; 10: 274.

Korpela K, Zijlmans MAC, Kuitunen M, Kukkonen K, Savilahti E, Salonen A, et al. Childhood BMI in relation to microbiota in infancy and lifetime antibiotic use. Microbiome 2017; 5: 26.

Kataoka K. The intestinal microbiota and its role in human health and disease. J Med Invest 2016; 63: 27-37.

Burcelin R. Gut microbiota and immune crosstalk in metabolic disease. Mol Metab 2016; 5: 771-81.

Lazar V, Ditu LM, Pircalabioru GG, Gheorghe I, Curutiu C, Holban AM, et al. Aspects of gut microbiota and immune system interactions in infectious diseases, immunopathology and cancer. Front Immunol 2018; 9: 1830.

Vemuri RC, Gundamaraju R, Shinde T, Eri R. Therapeutic interventions for gut dysbiosis and related disorders in the elderly: antibiotics, probiotics or faecal microbiota transplantation? Benef Microbes 2017; 8: 179-92.

Tsukamoto T, Nakagawa M, Kiriyama Y, Toyoda T, Cao X. Prevention of Gastric Cancer: Eradication of Helicobacter Pylori and Beyond. Int J Mol Sci 2017; 18: 1699.

Federico A, Dallio M, DI Sarno R, Giorgio V, Miele L. Gut microbiota, obesity and metabolic disorders. Minerva Gastroenterol Dietol 2017; 63: 337-44.

Parkar SG, Kalsbeek A, Cheeseman JF. Potential role for the gut microbiota in modulating host circadian rhythms and metabolic health. Microorganisms 2019; 7: 41.

Voigt RM, Forsyth CB, Green SJ, Engen PA, Keshavarzian A. Circadian Rhythm and the Gut Microbiome. Int Rev Neurobiol 2016; 131: 193-205.

Liang X, Bushman FD, FitzGerald GA. Rhythmicity of the intestinal microbiota is regulated by gender and the host circadian clock. Proc Natl Acad Sci USA 2015; 112: 10479-84.

Kim YS, Unno T, Kim BY, Park MS. Sex differences in gut microbiota. World J Mens Health 2020; 38: 48-60.

Mueller S, Saunier K, Hanisch C, Norin E, Alm L, Midtvedt T, et al. Differences in fecal microbiota in different European study populations in relation to age, gender, and country: a cross-sectional study. Appl Environ Microbiol 2006; 72: 1027-33.

Flores R, Shi J, Fuhrman B, Xu X, Veenstra TD, Gail MH, et al. Fecal microbial determinants of fecal and systemic estrogens and estrogen metabolites: a cross-sectional study. J Transl Med 2012; 10: 253.

Fuhrman BJ, Feigelson HS, Flores R, Gail MH, Xu X, Ravel J, et al. Associations of the fecal microbiome with urinary estrogens and estrogen metabolites in postmenopausal women. The J Clin Endocrinol Metab 2014; 99: 4632-40.

Mangiola F, Ianiro G, Franceschi F, Fagiuoli S, Gasbarrini G, Gasbarrini A. Gut microbiota in autism and mood disorders. World J Gastroenterol 2016; 22: 361-8.

Frati F, Salvatori C, Incorvaia C, Bellucci A, Di Cara G, Marcucci F, et al. The role of the microbiome in Asthma: The Gut-Lung axis. Int J Mol Sci 2019; 20: 123.

Azad MB, Konya T, Guttman DS, Field CJ, Sears MR, HayGlass K, et al. Infant gut microbiota and food sensitization: associations in the first year of life. Clin Exp Allergy 2015; 45: 632-43.

Wang B, Yao M, Lv L, Ling Z, Li L. The human microbiota in health and disease. Engineering 2017; 3: 71-82.

Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol 2016; 16: 626-38.

Ma Z, Li W. How and Why Men and Women Differ in Their Microbiomes: Medical Ecology and Network Analyses of the Microgenderome. Adv Sci (Weinh) 2019; 6: 1902054.

Levy G, Solt I. The human microbiome and gender medicine. Gender and the Genome 2018; 2: 123-7.

Vemuri R, Sylvia KE, Klein SL, Forster SC, Plebanski M, Eri R, et al. The microgenderome revealed: sex differences in bidirectional interactions between the microbiota, hormones, immunity and disease susceptibility. Semin Immunopathol 2019; 41: 265-75.

Zimmermann-Kogadeeva M, Zimmermann M, Goodman AL. Insights from pharmacokinetic models of host-microbiome drug metabolism. Gut Microbes 2020; 11: 587-96.

Matuskova Z, Anzenbacherova E, Vecera R, Tlaskalova-Hogenova H, Kolar M, Anzenbacher P. Administration of a probiotic can change drug pharmacokinetics: effect of E. coli Nissle 1917 on amidarone absorption in rats. PLoS One 2014; 9: e87150.

Hashim H, Azmin S, Razlan H, Yahya NW, Tan HJ, Manaf MRA, et al. Eradication of Helicobacter pylori infection improves levodopa action, clinical symptoms and quality of life in patients with Parkinson’s disease. PLoS One 2014; 9: e112330.

Kaddurah-Daouk R, Baillie RA, Zhu H, Zeng ZB, Wiest MM, Nguyen UT, et al. Enteric microbiome metabolites correlate with response to simvastatin treatment. PLoS One 2011; 6: e25482.

Saitta KS, Zhang C, Lee KK, Fujimoto K, Redinbo MR, Boelsterli UA. Bacterial beta- glucuronidase inhibition protects mice against enteropathy induced by indomethacin, ketoprofen or diclofenac: mode of action and pharmacokinetics. Xenobiotica 2014; 44: 28-35.

Roberts AB, Wallace BD, Venkatesh MK, Mani S, Redinbo MR. Molecular insights into microbial beta-glucuronidase inhibition to abrogate CPT-11 toxicity. Mol Pharmacol 2013; 84: 208-17.

Haiser HJ, Seim KL, Balskus EP, Turnbaugh P J. Mechanistic insight into digoxin inactivation by Eggerthella lenta augments our understanding of its pharmacokinetics. Gut microbes 2014; 5(2): 233-238. doi: 10.4161/gmic.27915

Stavropoulou E, Pircalabioru GG, Bezirtzoglou E. The Role of Cytochromes P450 in Infection. Front Immunol 2018; 31: 89.

Murphy CD. Drug metabolism in microorganisms. Biotechnol Lett 2015; 37: 19-28.

Bezirtzoglou EEV. Intestinal cytochromes P450 regulating the intestinal microbiota and its probiotic profile. Microb Ecol Health Dis 2012; 23.

Zhang J, Zhang J, Wang R. Gut microbiota modulates drug pharmacokinetics. Drug Metab Rev 2018; 50: 357-68.

Dempsey JL, Cui JY. Microbiome is a functional modifier of P450 drug metabolism. Current Pharmacology Reports 2019; 5: 481-90.

Sang H, Hulvey JP, Green R, Xu H, Im J, Chang T, et al. A xenobiotic detoxification pathway through transcriptional regulation in filamentous fungi. MBio 2018; 9: e00457-18.

Kim JK, Choi MS, Jeong JJ, Lim SM, Kim IS, Yoo HH, et al. Effect of probiotics on pharmacokinetics of orally administered acetaminophen in mice. Drug Metab Dispos 2018; 46: 122-30.

Downloads

Published

2020-12-01

How to Cite

Cesur, B., & Dora, D. D. (2020). Gut Microbiota: Formation, Lifelong Development and Relation to Cytochrome P450 System, Diseases, Drug Bioavailability and Drug Interactions. European Journal of Therapeutics, 26(4), 344–349. https://doi.org/10.5152/eurjther.2020.19098

Issue

Section

Review Articles